{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T14:02:47Z","timestamp":1765375367811,"version":"3.46.0"},"reference-count":5,"publisher":"Danish Medical Association","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ugeskr L\u00e6ger"],"abstract":"<jats:p>In this case report, a 73-year-old male with metastatic prostate cancer is presented. After progression on available standard treatments, he was enrolled in a precision medicine program. Re-biopsy revealed a defect in mismatch repair and an Activin A receptor type 2A mutation associated with high microsatellite instability. Pembrolizumab was started with clinical response, tumor regression, PSA-decline, and no adverse reactions. After 5 months, the treatment is ongoing. This illustrates that pembrolizumab can have an effect in some patients with prostate cancer and underscores the importance of molecular diagnostics.<\/jats:p>","DOI":"10.61409\/v05250410","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T12:06:03Z","timestamp":1764072363000},"page":"1-4","source":"Crossref","is-referenced-by-count":0,"title":["Pembrolizumab treatment of prostate cancer"],"prefix":"10.61409","author":[{"given":"Anne Hauge","family":"Thostrup","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Carus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morten","family":"Ladekarl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Astrid Johanneson","family":"Hjelholt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"40208","published-online":{"date-parts":[[2025,11,24]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"Raychaudhuri R, Lin DW, Montgomery RB. Prostate cancer: a review. JAMA. 2025;333(16):1433-1446. https:\/\/doi.org\/10.1001\/jama.2025.0228","DOI":"10.1001\/jama.2025.0228"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Duffy MJ, Crown J. Biomarkers for predicting response to immunotherapy with immune checkpoint inhibitors in cancer patients. Clin Chem. 2019;65(10):1228-1238. https:\/\/doi.org\/10.1373\/clinchem.2019.303644","DOI":"10.1373\/clinchem.2019.303644"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Venkatachalam S, McFarland TR, Agarwal N, Swami U. Immune checkpoint inhibitors in prostate cancer. Cancers (Basel). 2021;13(9):2187. https:\/\/doi.org\/10.3390\/cancers13092187","DOI":"10.3390\/cancers13092187"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Ladekarl M, N\u00f8hr AK, S\u00f8nderk\u00e6r M et al. Feasibility and early clinical impact of precision medicine for late-stage cancer patients in a regional public academic hospital. Acta Oncol. 2023;62(3):261-271. https:\/\/doi.org\/10.1080\/0284186X.2023.2185542 Epub 11. mar 2023","DOI":"10.1080\/0284186X.2023.2185542"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Mosalem O, Tan W, Bryce AH et al. A real-world experience of pembrolizumab monotherapy in microsatellite instability-high and\/or tumor mutation burden-high metastatic castration-resistant prostate cancer: outcome analysis. Prostate Cancer Prostatic Dis. 2025;28(1):138-144. https:\/\/doi.org\/10.1038\/s41391-024-00799-y Epub 10. feb 2024","DOI":"10.1038\/s41391-024-00799-y"}],"container-title":["Ugeskrift for L\u00e6ger"],"original-title":[],"deposited":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T13:40:13Z","timestamp":1765374013000},"score":1,"resource":{"primary":{"URL":"https:\/\/ugeskriftet.dk\/videnskab\/V05250410"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,24]]},"references-count":5,"URL":"https:\/\/doi.org\/10.61409\/v05250410","relation":{},"ISSN":["0041-5782","1603-6824"],"issn-type":[{"type":"print","value":"0041-5782"},{"type":"electronic","value":"1603-6824"}],"subject":[],"published":{"date-parts":[[2025,11,24]]}}}